ProKidney Corp Net Worth
ProKidney Corp Net Worth Breakdown | PROK |
ProKidney Corp Net Worth Analysis
ProKidney Corp's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including ProKidney Corp's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of ProKidney Corp's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform ProKidney Corp's net worth analysis. One common approach is to calculate ProKidney Corp's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares ProKidney Corp's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing ProKidney Corp's net worth. This approach calculates the present value of ProKidney Corp's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of ProKidney Corp's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate ProKidney Corp's net worth. This involves comparing ProKidney Corp's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into ProKidney Corp's net worth relative to its peers.
To determine if ProKidney Corp is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ProKidney Corp's net worth research are outlined below:
| ProKidney Corp generated a negative expected return over the last 90 days | |
| ProKidney Corp has high historical volatility and very poor performance | |
| ProKidney Corp may become a speculative penny stock | |
| ProKidney Corp has high likelihood to experience some financial distress in the next 2 years | |
| ProKidney Corp currently holds 4.41 M in liabilities with Debt to Equity (D/E) ratio of 5.66, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ProKidney Corp has a current ratio of 0.73, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about ProKidney Corp's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (135.45 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ProKidney Corp currently holds about 21.88 M in cash with (90.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36. | |
| ProKidney Corp has a very weak financial position based on the latest SEC disclosures | |
| Roughly 27.0% of ProKidney Corp outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: ProKidney to Participate in Two Upcoming Conferences Evercore HealthCONx Conference and the Citi Global Healthcare Conference |
ProKidney Corp uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ProKidney Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ProKidney Corp's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know ProKidney Corp's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ProKidney Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ProKidney Corp backward and forwards among themselves. ProKidney Corp's institutional investor refers to the entity that pools money to purchase ProKidney Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Nuveen Asset Management, Llc | 2024-06-30 | 288 K | Bank Of New York Mellon Corp | 2024-06-30 | 179.2 K | Alps Advisors Inc | 2024-09-30 | 97.4 K | Millennium Management Llc | 2024-06-30 | 91.9 K | Alliancebernstein L.p. | 2024-06-30 | 84.2 K | Rhumbline Advisers | 2024-06-30 | 76.2 K | Citigroup Inc | 2024-09-30 | 75.2 K | Metlife Investment Management, Llc | 2024-09-30 | 62.7 K | Mariner Wealth Advisors Llc | 2024-06-30 | 51.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 28.9 M | Suvretta Capital Management, Llc | 2024-06-30 | 9.3 M |
Follow ProKidney Corp's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.81 B.Market Cap |
|
Project ProKidney Corp's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.08) | (0.09) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.08) | (0.09) | |
| Return On Equity | 0.03 | 0.03 |
When accessing ProKidney Corp's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures ProKidney Corp's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ProKidney Corp's profitability and make more informed investment decisions.
Evaluate ProKidney Corp's management efficiency
ProKidney Corp has return on total asset (ROA) of (0.2037) % which means that it has lost $0.2037 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3134) %, meaning that it created substantial loss on money invested by shareholders. ProKidney Corp's management efficiency ratios could be used to measure how well ProKidney Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 0.03 this year, although the value of Return On Tangible Assets will most likely fall to (0.09). Total Current Liabilities is expected to rise to about 26.3 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 223.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.34 | 6.66 | |
| Tangible Book Value Per Share | 6.34 | 6.66 | |
| Enterprise Value Over EBITDA | (0.36) | (0.38) | |
| Price Book Value Ratio | (0.10) | (0.09) | |
| Enterprise Value Multiple | (0.36) | (0.38) | |
| Price Fair Value | (0.10) | (0.09) | |
| Enterprise Value | -59.1 M | -62.1 M |
The management team at ProKidney Corp has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Return On Equity (0.31) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ProKidney Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on ProKidney Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ProKidney Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ProKidney Corp time-series forecasting models is one of many ProKidney Corp's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ProKidney Corp's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
ProKidney Corp Earnings per Share Projection vs Actual
ProKidney Corp Corporate Management
| Aparna MD | VP Development | Profile | |
| Joseph MD | VP Devel | Profile | |
| Ashley Johns | VP Operations | Profile | |
| Carla Poulson | Chief Officer | Profile | |
| James CPA | Chief Officer | Profile | |
| Richard Williams | Senior Technology | Profile | |
| Kerry MD | VP Affairs | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProKidney Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy ProKidney Stock please use our How to buy in ProKidney Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProKidney Corp. If investors know ProKidney will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProKidney Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Return On Assets (0.20) | Return On Equity (0.31) |
The market value of ProKidney Corp is measured differently than its book value, which is the value of ProKidney that is recorded on the company's balance sheet. Investors also form their own opinion of ProKidney Corp's value that differs from its market value or its book value, called intrinsic value, which is ProKidney Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProKidney Corp's market value can be influenced by many factors that don't directly affect ProKidney Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProKidney Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if ProKidney Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProKidney Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.